SCHEDULE 13D/A: Others
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Transaction in Own Shares
6-K: Blujepa (Gepotidacin) Approved by Us Fda for Treatment of Uncomplicated Urinary Tract Infections (Uutis) in Female Adults and Paediatric Patients 12 Years of Age and Older
6-K: Transaction in Own Shares
6-K: Notice of Annual General Meeting of Shareholders 2025
6-K: Gsk's Application to Expand Use of Nucala (Mepolizumab) for the Treatment of Copd Accepted for Review by the European Medicines Agency
6-K: Transaction in Own Shares
6-K: Transaction Notification
6-K: Transaction in Own Shares
6-K: Transaction in Own Shares
6-K: Transaction in Own Shares
CERT: Others
CERT: Others
6-K: Transaction in Own Shares
6-K: Transaction in Own Shares
6-K: Transaction Notification
6-K: Transaction in Own Shares